CD38 and Miyoshi myopathy: In vitro and in vivo, it proved that P-R@Ni3P-BTZ has excellent targeting ability to CD38+ MM cells and is highly effective in killing MM cells by cooperating with photothermal therapy by Ni3P and chemotherapy by BTZ.